Health news
The pandemic has likely affected individuals vulnerable for developing eating disorders, as there has been an increased trend of inpatient hospitalizations. These findings were published as a research letter in JAMA Network Open. This study…
High sitting time during the COVID-19 pandemic was associated with depression, according to the results of a study published in Frontiers in Psychiatry. This longitudinal study analyzed data from the COVID-19 and the Wellbeing Study…
Lithium added to usual care did not decrease suicide-related events among veterans with major depression or bipolar disorder. These findings were published in JAMA Psychiatry. Veterans (N=519) who had an inpatient admission to prevent suicide…
Among early-career physician parents in the United States who served during the COVID-19 pandemic, mothers were more impacted by work-family struggles and mental health symptoms compared with fathers, according to research published in JAMA Network…
Utilizing placebo run-in (PRI) periods improves trial sensitivity, researchers found in a systematic review and meta-analysis published in JAMA Psychiatry. The researchers searched MEDLINE, Embase, PsycINFO, and Cochrane databases through July 2021 for original double-blind,…
The Food and Drug Administration (FDA) has approved Caplyta (lumateperone) for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.…
Racial and ethnic disparities exist in patients with depression, according to a recent retrospective analysis published in the Lancet Psychiatry. The authors believe the study is among the first to show patient preference for culturally…
While cultural attitudes toward animals may vary, researchers note there is a “commonly held belief that pets can improve the overall quality of human life.”1 In fact, there appears to be growing recognition of the…
Among patients recovering from an ischemic or hemorrhagic stroke, treatment with fluoxetine vs placebo did not decrease symptoms of clinically significant depression, according to study findings published in JAMA Neurology. The current study was a…
The Food and Drug Administration (FDA) has cleared BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) system for the reduction of comorbid anxiety symptoms in adult patients with depression, expanding the indication beyond treatment of depressive…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021